Position in ABBV
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$985,170
+$157,186 QoQ
Shares Held
3,915
+2.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#2,557
of 4,153 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Allen Capital Group, LLC holds $17,687,025 across 8 Drug Manufacturers - General names. ABBV ranks #6 (5.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
218,728 | $5,266,970 | |
| 2 | NVO |
Novo Nordisk A S
|
76,530 | $3,668,848 | |
| 3 | JNJ |
Johnson & Johnson
|
12,012 | $3,050,687 | |
| 4 | LLY |
ELI LILLY & Co
|
2,102 | $2,521,202 | |
| 5 | MRK |
Merck & Co., Inc.
|
10,589 | $1,360,686 | |
| 6 | ABBV |
AbbVie Inc.
This page
|
3,915 | $985,170 | |
| 7 | AMGN |
Amgen Inc
|
1,428 | $517,107 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
2,504 | $316,355 |
All Filings in ABBV
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $985,170 | 3,915 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $827,984 | 3,807 | Shares | Sole | 2026-05-27 | |
| 2025-12-31 | $776,409 | 3,398 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $739,770 | 3,195 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $597,139 | 3,217 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $601,112 | 2,869 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $493,650 | 2,778 | Shares | Sole | 2025-01-23 | |
| 2024-09-30 | $482,048 | 2,441 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $370,826 | 2,162 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $357,826 | 1,965 | Shares | Sole | 2024-04-15 | |
| 2023-12-31 | $248,571 | 1,604 | Shares | Sole | 2024-01-30 | |
| No filing history on record for this holder in this stock. | ||||||